CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer

被引：0
|
作者：
Smith, Matthew Raymond
Piulats, Josep M.
Todenhofer, Tilman
Lee, Jae-Lyun
Arija, Jose Angel Arranz
Mazilu, Laura
Azad, Arun
Alonso-Gordoa, Teresa
McGovern, Ursula Brigid
Choudhury, Atish Dipankar
Ye, Dingwei
Suzuki, Hiroyoshi
Mckay, Rana R.
Ades, Steven
Flechon, Aude
Pieczonka, Christopher Michael
Hulstijn, Maarten
Lithio, Andrew
Nacerddine, Karim
Agarwal, Neeraj
机构：
[1] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[2] Inst Catal Oncol Bellvitge Inst Biomed Res, Barcelona, Spain
[3] Studienpraxis Urol, Nurtingen, Germany
[4] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] Hosp Univ Gregorio Maranon, Madrid, Spain
[6] Clin Emergency Hosp, Constanta, Romania
[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[8] Hosp Univ Ramon y Cajal, Med Oncol Dept, Madrid, Spain
[9] Univ Coll Hosp London, London, England
[10] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[11] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[12] Toho Univ, Sakura Med Ctr, Chiba, Japan
[13] Univ Calif San Diego, La Jolla, CA USA
[14] Univ Vermont, Larner Coll Med, Burlington, VT USA
[15] Ctr Leon Berard, Lyon, France
[16] Associated Med Professionals NY, Syracuse, NY USA
[17] Eli Lilly & Co, Indianapolis, IN USA
[18] Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5001
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer
    Ojemuyiwa, Michelle A.
    Karzai, Fatima H.
    Shah, Avani Atul
    Theoret, Marc Robert
    Harold, Nancy
    Chun, Guinevere
    Couvillon, Anna
    Apolo, Andrea Borghese
    Price, Douglas K.
    Madan, Ravi Amrit
    Figg, William Douglas
    Gulley, James L.
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [42] Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study
    Cicero, Giuseppe
    De Luca, Rossella
    Blasi, Livio
    Pepe, Alessio
    Pavone, Carlo
    Simonato, Alchiede
    Dieli, Francesco
    ANTI-CANCER DRUGS, 2017, 28 (09) : 1047 - 1052
  • [43] A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
    Lin, Jianqing
    Patel, Sheel A.
    Sama, Ashwin R.
    Hoffman-Censits, Jean H.
    Kennedy, Brooke
    Kilpatrick, Deborah
    Ye, Zhong
    Yang, Hushan
    Mu, Zhaomei
    Leiby, Benjamin
    Lewis, Nancy
    Cristofanilli, Massimo
    Kelly, William Kevin
    ONCOLOGIST, 2016, 21 (11): : 1296 - 1297
  • [44] Abiraterone acetate in castration-resistant prostate cancer
    Iacovelli, Roberto
    Palazzo, Antonella
    Procopio, Giuseppe
    Gazzaniga, Paola
    Cortesi, Enrico
    ANTI-CANCER DRUGS, 2012, 23 (03) : 247 - 254
  • [45] Effects of Abiraterone Acetate on Chronic Kidney Disease in 2 Patients With Metastatic Castration-resistant Prostate Cancer
    Francini, Edoardo
    Petrioli, Roberto
    Fiaschi, Anna Ida
    Laera, Letizia
    Roviello, Giandomenico
    MEDICINE, 2014, 93 (27)
  • [46] Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine
    Lim, Emerson A.
    Petrylak, Daniel P.
    Peng, Weimin
    Kheoh, Thian
    Maul, Scott
    Smit, Johan W.
    Gonzalez, Martha D.
    De Porre, Peter
    NamPhuong Tran
    Nanus, David M.
    EUROPEAN UROLOGY, 2016, 70 (05) : 718 - 721
  • [47] Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
    Chi, Kim N.
    Fleshner, Neil
    Chiuri, Vincenzo Emanuele
    Van Bruwaene, Siska
    Hafron, Jason
    McNeel, Douglas G.
    De Porre, Peter
    Maul, Raymond Scott
    Daksh, Mahesh
    Zhong, Xiaogang
    Mason, Gary E.
    Tutrone, Ronald F.
    ONCOLOGIST, 2023, 28 (05): : E309 - E312
  • [48] CYCLONE 1: A phase 2 study of abemaciclib in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a novel hormonal agent and taxane-based chemotherapy.
    Agarwal, Neeraj
    Oudard, Stephane
    Piulats, Josep M.
    Schweizer, Michael Thomas
    Flechon, Aude
    Gordoa, Teresa Alonso
    Nacerddine, Karim
    Lithio, Andrew
    Johnston, Erica L.
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Beyond abiraterone New hormonal therapies for metastatic castration-resistant prostate cancer
    Pinto, Alvaro
    CANCER BIOLOGY & THERAPY, 2014, 15 (02) : 149 - 155
  • [50] Abiraterone Acetate, A Novel Adrenal Inhibitor in Metastatic Castration-Resistant Prostate Cancer
    Salem, Mohamed
    Garcia, Jorge A.
    CURRENT ONCOLOGY REPORTS, 2011, 13 (02) : 92 - 96
12345